AstraZeneca's Q1 Financial Performance

AstraZeneca PLC has announced a notable 7% increase in revenue for the first quarter of fiscal year 2025, reaching $13.6 billion. This growth reflects a 10% rise at constant exchange rates (CER), showcasing the company's robust financial health.

Product Sales and Earnings Surge

The pharmaceutical giant reported a 6% increase in product sales, which amounts to $12.9 billion at CER. Additionally, the core operating profit saw a 12% growth, with reported earnings per share (EPS) jumping by 35% to $1.88.

Future Outlook

Looking ahead, AstraZeneca anticipates a high single-digit percentage increase in total revenue for 2025, alongside a low double-digit rise in core EPS. "We are on track to achieve our ambitious goal of $80 billion in Total Revenue by 2030," stated CEO Pascal Soriot, emphasizing the company's commitment to growth and investment in the US market.